- Home
- CNTX vs BMEA Comparison
CNTX vs BMEA Comparison
Compare CNTX & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- BMEA
- Stock Information
- Founded
- CNTX 2015
- BMEA 2017
- Country
- CNTX United States
- BMEA United States
- Employees
- CNTX N/A
- BMEA N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- CNTX Health Care
- BMEA Health Care
- Exchange
- CNTX Nasdaq
- BMEA Nasdaq
- Market Cap
- CNTX 78.0M
- BMEA 65.8M
- IPO Year
- CNTX 2021
- BMEA 2021
- Fundamental
- Price
- CNTX $0.81
- BMEA $1.66
- Analyst Decision
- CNTX Strong Buy
- BMEA Strong Buy
- Analyst Count
- CNTX 5
- BMEA 10
- Target Price
- CNTX $5.50
- BMEA $21.00
- AVG Volume (30 Days)
- CNTX 193.2K
- BMEA 987.2K
- Earning Date
- CNTX 08-06-2025
- BMEA 08-04-2025
- Dividend Yield
- CNTX N/A
- BMEA N/A
- EPS Growth
- CNTX N/A
- BMEA N/A
- EPS
- CNTX N/A
- BMEA N/A
- Revenue
- CNTX N/A
- BMEA N/A
- Revenue This Year
- CNTX N/A
- BMEA N/A
- Revenue Next Year
- CNTX N/A
- BMEA N/A
- P/E Ratio
- CNTX N/A
- BMEA N/A
- Revenue Growth
- CNTX N/A
- BMEA N/A
- 52 Week Low
- CNTX $0.49
- BMEA $1.29
- 52 Week High
- CNTX $2.75
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- CNTX 57.85
- BMEA 40.83
- Support Level
- CNTX $0.82
- BMEA $1.72
- Resistance Level
- CNTX $0.88
- BMEA $1.85
- Average True Range (ATR)
- CNTX 0.07
- BMEA 0.11
- MACD
- CNTX 0.00
- BMEA -0.01
- Stochastic Oscillator
- CNTX 42.87
- BMEA 5.41
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.